BHOCTHERAPEUTICS

Sepsis, Microcirculation & Tissue Oxygenation

Why effective oxygen delivery in critical illness must be considered beyond hemoglobin concentration, arterial saturation and macrocirculatory parameters.

Why can tissue oxygenation be impaired during severe inflammation?

The reviewed physiology links inflammation, endothelial dysfunction, edema and disturbed microcirculation with impaired oxygen transport from blood to tissues. The analysis follows oxygen delivery beyond blood oxygen content alone.

In this article
  1. 1. The Review
  2. 2. What the Review Shows
  3. 3. From Blood Oxygen to Tissue Oxygenation
  4. 4. Relevance to BHOC and HBOC Research
  5. 5. Endothelium, Nitric Oxide and Microcirculation
  6. 6. Precision Oxygen Therapeutics
  7. 7. BHOC Evidence Context
  8. Original Scientific Source
  9. Inflammation, oxygen demand and metabolism
  10. Organ dysfunction and model-specific evidence
  11. Monitor perfusion, oxygenation and metabolism separately

1. The Review

Article: Nimmo A, Younsi A. The Potential for Severe, Acute Inflammation to Impact Tissue Oxygenation-A Narrative Review. Oxygen. 2026;6(3):22.

DOI10.3390/oxygen6030022
PublisherMDPI / Oxygen ↗

2. What the Review Shows

The review describes how severe, dysregulated acute inflammation can compromise tissue oxygenation through vascular mechanisms operating at both the macrocirculatory and microcirculatory levels. Increased vascular permeability and edema can increase the distance over which oxygen must diffuse, while altered perfusion, coagulation and endothelial dysfunction can further restrict effective oxygen delivery to tissues.

Key point: oxygen present in the bloodstream does not automatically mean adequate oxygen availability in the tissue. Perfusion, diffusion distance, endothelial function and microcirculatory flow all influence the final physiological result.

3. From Blood Oxygen to Tissue Oxygenation

In severe inflammation, sepsis and shock, the oxygen-delivery problem can extend beyond a single number such as hemoglobin concentration, SpO₂ or blood pressure. The clinically relevant endpoint is the ability of oxygen to reach cells and support tissue metabolism.

Oxygen carriage → blood flow → microcirculation → diffusion → tissue oxygen availability.

This broader pathway is central to the scientific framework of Precision Oxygen Therapeutics: evaluating oxygen support according to functional tissue oxygen delivery rather than relying on one systemic surrogate alone.

4. Relevance to BHOC and HBOC Research

This publication does not evaluate BHOC or an HBOC product directly. Its importance for the BHOC evidence framework is pathophysiological: it defines conditions in which conventional oxygen transport can be limited by endothelial dysfunction, impaired microcirculation, edema and abnormal perfusion.

BHOC perspective: this provides a scientific rationale for investigating complementary oxygen-delivery platforms such as a Biological Hemoglobin Oxygen Carrier (BHOC) or other hemoglobin-based oxygen carriers (HBOCs) when RBC-dependent oxygen transport and normal vascular regulation may be insufficient. The research objective is not to replace all functions of red blood cells, but to determine whether tissue oxygen availability can be supported more precisely in critical conditions.

5. Endothelium, Nitric Oxide and Microcirculation

The review also places nitric oxide, endothelial function and vascular tone inside the tissue-oxygenation problem. In severe inflammatory states, NO biology is complex: systemic vasodilation, endothelial dysfunction and microvascular regulation can occur simultaneously.

For next-generation HBOC and BHOC development, this supports a more complete evaluation than asking only whether cell-free hemoglobin scavenges nitric oxide or produces vasoconstriction. The more functional question is the net effect on microvascular perfusion, oxygen unloading and tissue oxygen delivery.

Read: Nitric Oxide Scavenging, HBOC Vasoconstriction & Tissue Oxygenation →

6. Precision Oxygen Therapeutics

This review supports the pathophysiological rationale for a Precision Oxygen Therapeutics approach: moving from a macrocirculation-only view toward assessment of oxygen delivery at the tissue level.

In critical conditions, the limitation may extend beyond hemoglobin concentration or arterial oxygen saturation. RBC-dependent oxygen transport, endothelial dysfunction, impaired microcirculation, edema, vascular stasis and increased diffusion distance can all restrict effective tissue oxygenation.

Scientific objective: preserve and support tissue-level oxygen delivery with a more precise and controllable oxygenation strategy when conventional physiological mechanisms become insufficient.

7. BHOC Evidence Context

This page forms part of the broader BHOC scientific evidence platform. Related literature is indexed under both BHOC and legacy HBOC terminology, including research associated with HBOC-201 / Hemopure, Oxyglobin and historical Biopure programs. Product-specific evidence and claims remain separated from the pathophysiological rationale described in this review.

Original Scientific Source

Nimmo A, Younsi A. 2026. The Potential for Severe, Acute Inflammation to Impact Tissue Oxygenation-A Narrative Review. Oxygen. 6(3):22. DOI ↗ · Full article ↗

← Return to BHOC Science

Evidence qualification: the cited review concerns inflammation, vascular dysfunction and tissue oxygenation. It is used here as scientific context for oxygen-delivery research and does not establish safety, efficacy or clinical benefit for BHOC, HBOC-201, Hemopure, Oxyglobin or any other oxygen-carrier product.

Inflammation, oxygen demand and metabolism

The review discussed above addresses severe acute inflammation and tissue oxygenation. It is physiological context rather than a direct evaluation of BHOC or an HBOC product.

Questions about immunometabolism, inflammatory oxygen demand and cellular response need a specified model and endpoint. The proposed BHOC development question is whether controlled delivery changes a measured oxygen-exposure profile and functional response, not an assumption that adding a carrier resolves inflammation.

Organ dysfunction and model-specific evidence

An experimental organ-failure endpoint and clinical multiorgan dysfunction are different evidence settings. The catalogue contains a rat hemorrhagic-shock study of heme-based solutions, stress proteins and organ failure. It is not evidence that BHOC prevents human multiorgan failure.

A critical-care protocol should connect the perfusion measurement to a defined organ-function endpoint and retain the comparator, model and time course. Renal, hepatic, cardiac and cerebral outcomes should not be pooled into one generic benefit.

Monitor perfusion, oxygenation and metabolism separately

Dyson and Singer’s monitoring review is retained in the scientific additions. It addresses tissue perfusion, oxygenation and metabolism in critically ill patients. It provides measurement context, not an intervention result for BHOC.

A research programme should state what a lactate, oxygen-extraction, saturation or regional-perfusion measurement represents in its particular setting. A single result should not be treated as a complete description of every tissue or of mitochondrial function.

Page layout and discovery metadata updated . Original scientific content and source links retained.